National Pension Service Buys 6,885 Shares of IDEXX Laboratories, Inc. $IDXX

National Pension Service lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 129,305 shares of the company’s stock after acquiring an additional 6,885 shares during the quarter. National Pension Service owned approximately 0.16% of IDEXX Laboratories worth $68,071,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. California State Teachers Retirement System boosted its holdings in shares of IDEXX Laboratories by 50,115.1% in the second quarter. California State Teachers Retirement System now owns 61,590,848 shares of the company’s stock valued at $32,423,886,000 after purchasing an additional 61,468,194 shares during the period. Elyxium Wealth LLC purchased a new stake in shares of IDEXX Laboratories in the 4th quarter worth $3,666,459,000. State Street Corp lifted its holdings in shares of IDEXX Laboratories by 4.0% in the 4th quarter. State Street Corp now owns 3,656,626 shares of the company’s stock worth $2,473,817,000 after buying an additional 138,956 shares during the period. J. Stern & Co. LLP grew its position in shares of IDEXX Laboratories by 23,694.7% during the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after buying an additional 2,642,200 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of IDEXX Laboratories by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock worth $1,749,380,000 after buying an additional 86,263 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.4%

NASDAQ:IDXX opened at $504.70 on Friday. The company’s 50-day simple moving average is $555.59 and its 200-day simple moving average is $566.45. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. IDEXX Laboratories, Inc. has a fifty-two week low of $500.61 and a fifty-two week high of $769.98. The stock has a market capitalization of $39.76 billion, a P/E ratio of 35.49, a P/E/G ratio of 2.70 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Citigroup upped their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. UBS Group raised their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Barclays lowered their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Six research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $747.00.

Insider Activity at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director owned 9,568 shares in the company, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.79% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.